Prove efficacy of Itolizumab for subcutaneous route: CDSCO panel Tells Biocon Biologics
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the drug major Biocon Biologics conduct a clinical trial of Itolizumab for Injection 100mg/vial for a new route of administration, subcutaneous route to prove that the efficacy of the product is similar with the already approved intravenous route for the product treatment of moderate-to-severe chronic plaque psoriasis.
This came after the drug major Biocon Biologics presented their proposal for approval of a subcutaneous route of administration in addition to the approved intravenous route for the product Itolizumab for Injection 100mg/vial for the approved indication i.e., treatment of moderate to severe chronic plaque psoriasis.
Itolizumab is a 'first in class' humanized IgG1 monoclonal antibody developed by Biocon and the Center of Molecular Immunology (CIM), Havana. Itolizumab is Biocon’s second ‘lab to market’ novel biologic after Nimotuzumab and offers a ‘best-in-class’ biologic drug for acute psoriasis.
Itolizumab binds to CD6 which modulates T-lymphocyte activation and proliferation. It is an efficacious immunomodulatory compound investigated for treating psoriasis. Currently, the full mechanisms of action are still unclear.
At the recent SEC meeting for Dermatology and Allergy held on 17th August 2023, the expert panel reviewed the proposal presented by Biocon Biologics for approval of a subcutaneous route of administration in addition to the approved intravenous route for the product Itolizumab for Injection 100mg/vial for the approved indication i.e., treatment of moderate to severe chronic plaque psoriasis.
After detailed deliberation, the committee recommended that the firm should conduct a clinical trial for a new route of administration i.e. subcutaneous route to prove that the efficacy of the product is similar to the already approved route of administration in the proposed indication.
Accordingly, the expert panel suggested that the firm should submit the clinical trial protocol to CDSCO for review by the committee
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.